Report for Q3 2026
The abstract is for reference only. Please refer to the full text of the announcement on the very day.
(603367)"Cisen Pharmaceutical Co., Ltd."Report for Q3 2026
Filed with SSE · Stock code 603367 ·
6ix is reading this filing.
View original source (Shanghai Stock Exchange)Cisen Pharmaceutical Ltd. on 6ix
Earlier from Cisen Pharmaceutical
- Announcement on Resolutions of the 1st Extraordinary General Meeting in 2026
- Announcement on a Subsidiary's Receipt of the First Generic Approval for Marketing of Its Loteprednol Etabonate and Tobramycin Eye Drops
- Announcement on Implementation of Dividend Distribution for the First Half of 2026
- Announcement on Outline of the 2026 Semi-annual Performance and Cash Dividend Briefing
- Notice on Convening the 1st Extraordinary General Meeting in 2026
Follow Cisen Pharmaceutical into a list and get an email when it puts out news.
Follow Cisen Pharmaceutical